TRI.TO -0.02C -1.89GFL.TO 2.01BRK.B -4.78PLUS -0.79TGTX 1.01LLY -33.23SU.TO 2.79
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

30.03
-0.39 (1.28%)
as of Oct 23, 2026, 8:00:00 pm Market Closed.
585 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
DON'T BUY

Pfizer Inc(PFE)

Oct 12, 2011
Suffering from loosing their patent on lipitor. Will be a pullback on earnings. Trying to reassess their businesses and potentially spinning some off. Not a big fan of large cap Pharma. Prefers diversified health care companies like Abbot.
Photo of Christine PooleChristine PooleUnlock Rating
$18.82

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Track your Stocks in your Watch List
TOP PICK

Pfizer Inc(PFE)

Sep 23, 2011
Debt rating cut but it doesn’t matter to him. They all have the patent cliff. He likes that they bought Wyeth who have a lot of drugs on patent. People say PFE is too big to make a difference if a new drug comes along so they are shrinking the company. Big, safe dividends.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$17.45

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 28, 2011
Lipitor is coming off patent and accounts for a boat 20% of their revenues. Sales are expected to drop about 5% next year.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$19.36

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jul 22, 2011
Largest drug company in the world. Good pipeline, but they have been paring it down to focus on new drugs. Prefers Teva.
Photo of Richard FoglerRichard Fogler
No
Unlock Rating
$20.07

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Jun 16, 2011
This would be his 2nd choice after Eli Lilly (LLY-N). Facing the issue of a patent cliff where drugs are coming off patent. Has about 4 drugs expecting to move into phase 3 trials. Very attractive multiple. Good dividend yield.
Photo of Mohsin BashirMohsin BashirUnlock Rating
$20.24

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

May 12, 2011
Largest global pharma. Likes it. Whole pharma sector has been suffering from a lack of new block buster drugs. This one is facing the expiration of the patent on their Lipitor drug but this is already reflected in the stock price. Have some very promising drugs in phase 2 and 3 clinical trials. Stock is not expensive and has a 4% yield.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$20.89

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 27, 2011
Has done well lately on the potential of it breaking up and selling off the pieces. The difficulty in the whole pharma sector is that it is tough to grow.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$20.63

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 06, 2011
Likes this one especially because they have announced they are going to downsize the company and shareholders will be rewarded for that. Selling a capsule manufacturing company for $2.5 billion.
Photo of Norman LevineNorman LevineUnlock Rating
$20.29

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 25, 2011
Drug sector is all suffering from same thing – drugs coming off patent faster than entering the pipeline. Are trying to rebuild themselves. They are all trying to get their costs down.
Photo of Lorne SteinbergLorne SteinbergUnlock Rating
$20.35

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 24, 2011
Thinks it is turning around. Very good yield. Have a difficult time with some of the blockbuster drugs coming off patent.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$20.30

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Mar 15, 2011
Are breaking themselves up after a string of acquisitions. He sees this happening. Want to get rid of their generics.
Photo of Don ReedDon ReedUnlock Rating
$19.76

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 28, 2011
New CEO is changing the company compared to the other pharmas. R&D has been a big pit for all companies and he is cutting this back. Will be basically be cutting the company into smaller parts.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$19.24

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 11, 2011
Not keen on the big pharma complex at this stage. This one in particular has had struggles with their pipeline. There are better ways to play the health care space.
Photo of Karl BergerKarl BergerUnlock Rating
$18.83

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 05, 2011
(A Top Pick Feb 3/10. Down 0.29%.) Model price is $29.91, an upside of 62%. Good dividend. His earnings estimate shows $2.22. Still a Buy.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$18.11

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Dec 23, 2010
A lot of the pharmaceuticals have been in the doldrums for a long time. Large dividend yield and cheap on a PE basis but their large blockbuster drugs are coming off patent.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$17.61

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Showing 436 to 450 of 894 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AMZN -2.38$248
META -6.23$642.62
VRT -1.27$194.32
WFC -0.62$82.39
ZS 17.39$255.15

Today's Top Picks

TRI.TO -0.02$172.41
C -1.89$120.62
GFL.TO 2.01$63.75
BRK.B -4.78$542.19
PLUS -0.79$95.36

Popular Articles

Latest Sell Signals

DOV 0$
BA 0.8$188.35
AC.TO -1.03$21.11
BB.TO 0.44$12.46
TSM 6.16$418.51

Most Recent Experts

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jason Snipe, CIO, Odyssey Capital Advisors

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Tim Regan

Tim Regan

Kingwest & Company

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like